PTC THERAPEUTICS, INC.
SCHMERTZLER MICHAEL sold 25,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $72.22 ($70.78–$73.67, $1.81M total) across 5 trades over 2026-08-19 to 2026-08-20 under a Rule 10b5-1 trading plan.
PTC Therapeutics (PTCT) announced a planned resale of 50,000 common shares under Rule 144. The sale, expected to occur in the open market, is for the account of Michael Schmertzler via Section Six Partners, LP. The shares were acquired on July 4, 2012, and the aggregate market value of the securities owned is $3.65 million. As of August 19, 2026, PTCT had 83,460,802 shares outstanding.
Wells Fargo highlighted PTC Therapeutics (PTCT) and Dick’s Sporting Goods (DKS) as potential outperformers. For PTCT, it cited Q2 revenue of $360.5M (+101.5% YoY), EPS of $0.92, and raised full-year revenue guidance to $1.18B-$1.28B, with a $109 price target. For DKS, it pointed to fiscal Q1 revenue of $5.17B (+62%) and an Overweight rating with a $240 target.
Over the past 7 days, alphai's AI scored 2 news stories mentioning PTCT (PTC THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent PTCT coverage spans earnings, insider activity and financial news.
In the last 30 days, PTCT insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($2.7M). The most active reporter was SCHMERTZLER MICHAEL with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal reduced confidence or portfolio rebalancing, but the amount is modest relative to market cap.
The secondary‑market sale could create modest downward pressure on PTCT price.
Analyst thesis ties PTCT upside to Sephience adoption and pipeline progress, anchored by strong reported growth and guidance raise.
The ST-920 licensing/acquisition terms and planned FDA accelerated-approval BLA submission create a clear near-to-mid-term catalyst path for PTCT’s rare-disease pipeline.
The deal meaningfully expands PTC’s rare-disease pipeline with a BLA-stage AAV gene therapy, shifting near-term revenue and execution risk into 2026-2027 regulatory milestones.
alphai scores every news story that mentions PTCT with an AI model for sentiment and relevance, and aggregates insider trades from PTC THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SCHMERTZLER MICHAEL sold 25,000 indirectly-held shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $72.22 ($70.78–$73.67, $1.81M total) across 5 trades over 2026-08-19 to 2026-08-20 under a Rule 10b5-1 trading plan.
1 min readPTC Therapeutics (PTCT) announced a planned resale of 50,000 common shares under Rule 144. The sale, expected to occur in the open market, is for the account of Michael Schmertzler via Section Six Partners, LP. The shares were acquired on July 4, 2012, and the aggregate market value of the securities owned is $3.65 million. As of August 19, 2026, PTCT had 83,460,802 shares outstanding.
1 min readWells Fargo highlighted PTC Therapeutics (PTCT) and Dick’s Sporting Goods (DKS) as potential outperformers. For PTCT, it cited Q2 revenue of $360.5M (+101.5% YoY), EPS of $0.92, and raised full-year revenue guidance to $1.18B-$1.28B, with a $109 price target. For DKS, it pointed to fiscal Q1 revenue of $5.17B (+62%) and an Overweight rating with a $240 target.
4 min readPTC Therapeutics (NASDAQ:PTCT) agreed to expand its Fabry disease pipeline with ST-920, a one-time AAV gene therapy. The deal includes $111 million upfront and up to $100 million in contingent milestones tied to regulatory approvals. PTC expects a rolling FDA BLA for accelerated approval to finish in Q4 2026. PTCT shares were about $72.55.
4 min readPTC Therapeutics (PTCT) agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upfront plus milestones. PTC cites Phase 1/2 STAAR data and plans an accelerated approval BLA submission, with CMC due Q4 2026 and a 2027 launch. Close expected in Q3 2026.
4 min readPTC Therapeutics (PTCT) reported Q2 2026 revenue of $360.52M and net income of $83.5M, and raised its full-year 2026 total revenue outlook to $1.18B to $1.28B. The company also appointed Hege Sollie-Zetlmayer to its board. The update may affect investor views on profitability and guidance.
5 min readKlein Matthew B. (CHIEF EXECUTIVE OFFICER) sold 10,292 shares of PTC THERAPEUTICS, INC. (PTCT) at $68.57 ($0.71M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readSimply Wall St reports PTC Therapeutics (PTCT) shares fell nearly 10% after Q2 2026 results. The company posted Q2 revenue of about $360.5m vs $178.9m a year earlier, and moved to basic EPS of about $1.01 from a loss. Sephience generated $151m product revenue; cash was $2.23b.
6 min readNasdaq sees best day in over a month as Microsoft breathes life back into AI trade PTC Therapeutics reported stronger-than-expected second-quarter 2026 results, with earnings of $0.92 a share on revenue of $361 million, well ahead of Wall Street’s forecast for $0.32 a share and $293.1 million in sales. The company said the quarter reflected record revenue, led by Sephience, and raised its full-year outlook.
4 min read(PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B Published on 07/30/2026 at 04:48 pm EDT | Market Closed - Other stock markets | 5-day change | 1st Jan Change | || | 75.52 USD | +1.38% | -3.67% | -0.58% | | Jul. 30 | PTC Q2 Swings to Profit, Revenue Rises; Ups Guidance | MT | | Jul. 30 | PTC Therapeutics, Inc.
2 min read
